<SEC-DOCUMENT>0001654954-26-005024.txt : 20260518
<SEC-HEADER>0001654954-26-005024.hdr.sgml : 20260518
<ACCEPTANCE-DATETIME>20260518062935
ACCESSION NUMBER:		0001654954-26-005024
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260518
FILED AS OF DATE:		20260518
DATE AS OF CHANGE:		20260518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GSK plc
		CENTRAL INDEX KEY:			0001131399
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15170
		FILM NUMBER:		26990728

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		79 NEW OXFORD STREET
		CITY:			LONDON
		PROVINCE COUNTRY:   	X0
		ZIP:			WC1A 1DG
		BUSINESS PHONE:		44 20 8047 5000

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		79 NEW OXFORD STREET
		CITY:			LONDON
		PROVINCE COUNTRY:   	X0
		ZIP:			WC1A 1DG

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GSK PLC
		DATE OF NAME CHANGE:	20220516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLAXOSMITHKLINE PLC
		DATE OF NAME CHANGE:	20010105
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a5853e.htm
<DESCRIPTION>JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Services - www.issuerservices.net -->
<!-- Copyright 2026 Issuer Services -->
<title>a5853e</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNITED STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Washington, D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Form 6-K</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
month of May 2026</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number 001-15170</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
GSK plc</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Translation
of registrant's name into English)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
79 New Oxford Street, London, WC1A 1DG</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Address
of principal executive office)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Form
20-F . . . .X. . . . Form 40-F . . . . . . . .</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;Issued: 18 May 2026, London UK</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; color: #DC4133; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 24px">
GSK's RSV vaccine, Arexvy, receives expanded&#xA0;approval&#xA0;in
Japan for&#xA0;adults aged 18-59 at increased risk</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 16px">
&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 16px">&#x25CF;&#xA0; &#xA0;</font>
<font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 16px">First
RSV vaccine approved for adults aged 18-59 years at increased risk
and for all adults 60 years and older in Japan</font></font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000; font-size: 16px">&#x25CF;&#xA0; &#xA0;</font>
<font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 16px">In
Japan, millions of adults live with certain chronic conditions that
increase their risk of severe RSV outcomes</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[1]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><a name="_ednref2"><!--anchor--></a><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[2]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[3]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[4]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[5]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[6]</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #DC4133; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<br></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--line--></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
GSK plc (LSE/NYSE: GSK) today announced that Japan's Ministry of
Health, Labour and Welfare (MHLW) has expanded the eligible
population for</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="font-style: italic; color: #000000">Arexvy</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">(Respiratory
Syncytial Virus vaccine, [adjuvanted, recombinant]), to
include</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">adults
aged 18 to 49 years at increased risk (AIR) for RSV disease. GSK's
RSV vaccine was previously approved in Japan for the prevention of
RSV disease in all adults aged 60 years and older, and for adults
aged 50-59 AIR for RSV disease.</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">The
prescribing information for&#xA0;</font><font style="font-style: italic; color: #000000">Arexvy</font><font style="color: #000000">&#xA0;has also been updated to explicitly include
immuno-compromised (IC) patients as an increased risk group -
helping clinicians to identify people who may benefit from RSV
prevention.</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold; color: #000000">
Sanjay Gurunathan,</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="font-weight: bold; color: #000000">GSK
Head of Vaccines and Infectious Diseases Research and
Development,</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">said:</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
"This expanded approval, the first covering all at-risk adults in
Japan, can help reduce potentially severe outcomes of RSV. It
recognises the serious impact RSV can have for adults of any age
living with chronic conditions such as cardiovascular disease,
chronic obstructive pulmonary disease and asthma, and it enables
more people to take a proactive approach to disease
prevention."</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
RSV is a common and contagious respiratory virus that can cause
serious illness in adults, particularly those living with certain
chronic conditions.</font><font style="font-size: 70%; vertical-align: top; color: #000000">6,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[7]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[8]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">RSV
infection can cause major adverse cardiovascular events (MACE)
including heart attack and stroke,</font><font style="font-size: 70%; vertical-align: top; color: #000000">4,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[9]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[10]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[11]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[12]</font><font style="color: #000000">&#xA0;trigger
flare-ups of chronic obstructive pulmonary disease (COPD) and
asthma and may result in severe illness, hospitalisation, and even
death.</font><font style="font-size: 70%; vertical-align: top; color: #000000">6</font><font style="color: #000000">&#xA0;More
than 42&#x202F;million adults in Japan are aged
18-49</font><font style="font-size: 70%; vertical-align: top; color: #000000">1</font><font style="color: #000000">&#xA0;and,
while often considered at low risk of RSV, many in this group live
with underlying chronic conditions.</font><font style="font-size: 70%; vertical-align: top; color: #000000">2</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The approval was</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">supported
by data from a Phase IIIb trial</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">(</font><font style="text-decoration: underline; color: #0000FF">NCT06389487</font><font style="color: #000000">)
demonstrating a non-inferior immune response in adults aged 18 to
49 years AIR &#xA0;for RSV disease</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">compared
to adults aged 60 years and above.</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[13]</font><font style="color: #000000">&#xA0;Vaccine
efficacy was demonstrated in the earlier Phase III trial
(</font><font style="text-decoration: underline; color: #0000FF">NCT04886596</font><font style="color: #000000">).</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[14]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">The
safety profile was consistent with findings from the broader Phase
III programme that supported the initial
approval</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">with
the most common adverse events being injection site pain, myalgia,
fatigue, arthralgia and headache, which were largely transient and
mild to moderate in intensity.</font><font style="font-size: 70%; vertical-align: top; color: #000000">13</font><font style="color: #000000">&#xA0;The
update to the prescribing information to include IC
patients,</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">accepted
by</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">Japan's
Pharmaceuticals and Medical Devices Agency (PMDA),&#xA0;was
supported by data from a Phase IIb trial&#xA0;(</font><font style="text-decoration: underline; color: #0000FF">NCT05921903</font><font style="color: #000000">).</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[15]</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
GSK continues to advance</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #09090B">regulatory
submissions for its RSV vaccine across multiple geographies to
expand availability</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">and
support disease prevention.</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About GSK's RSV vaccine</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Respiratory Syncytial Virus vaccine (adjuvanted)
contains recombinant RSV glycoprotein F stabilised in the prefusion
conformation (RSVPreF3). This antigen is combined with GSK's
proprietary AS01</font><font style="font-size: 70%; vertical-align: bottom; color: #000000">E</font><font style="color: #000000">&#xA0;adjuvant
before administration.</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The use of this vaccine should be in accordance with official
recommendations.</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">As
with any vaccine, a protective immune response may not be elicited
in all vaccinees.</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The vaccine has been approved for the prevention of RSV-LRTD in
individuals 60 years of age and older in 70 countries. In addition,
it is approved for use in individuals aged 50-59 years who are at
increased risk due to certain underlying medical conditions in more
than 60 countries. In the US it is also approved in adults aged
18-49 years at increased risk, and in the European Economic Area
for all adults aged 18 years and older.</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[16]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[17]</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
The GSK proprietary AS01 adjuvant system contains STIMULON QS-21
adjuvant licensed from Antigenics LLC, a wholly owned subsidiary of
Agenus Inc. STIMULON is a trademark of SaponiQx Inc., a subsidiary
of Agenus.</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Please refer to the updated Product Information (PI) for
precautions concerning indications, dosage and administration and
safety information in Japan at this link:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">Japan
Pharmaceuticals and Medical Devices Agency</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[18]</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About the NCT06389487 trial</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">NCT06389487 is a Phase IIIb, open-label
multi-country immunogenicity trial to evaluate the non-inferiority
of the immune response and evaluate safety in participants aged
18-49 at increased risk for lower respiratory tract disease (LRTD)
caused by RSV (n=1,029), compared to participants aged 60 years and
above (n=429) after a single dose of GSK's RSV
vaccine.</font><font style="font-size: 70%; vertical-align: top; color: #000000">13</font><font style="color: #000000">&#xA0;Of
the 18-49 cohort, 426 were included in the immunogenicity analysis
and 603 were assessed for safety only.</font><font style="font-size: 70%; vertical-align: top; color: #000000">13</font><font style="color: #000000">&#xA0;A
total of 1,458 participants were enrolled across 52 locations in
six countries, including four sites in Japan.</font><font style="font-size: 70%; vertical-align: top; color: #000000">13</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The trial's primary endpoints were RSV-A and RSV-B neutralisation
titres expressed as mean geometric titre ratio (relative to older
adults over adults at increased risk) and sero-response rate in
RSV-A and RSV-B neutralising titres one month post vaccine
administration.</font><font style="font-size: 70%; vertical-align: top; color: #000000">13</font><font style="color: #000000">&#xA0;There
were also safety and immunogenicity secondary and tertiary
endpoints.</font><font style="font-size: 70%; vertical-align: top; color: #000000">13</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About the NCT04886596 trial</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">NCT04886596 is a Phase III, randomised,
placebo-controlled, observer-blind, multi-country trial to evaluate
vaccine efficacy of a single dose, and annual revaccination doses
of GSK's RSV vaccine, in preventing</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">RSV-LRTD</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">in
adults aged 60 years and above.</font><font style="font-size: 70%; vertical-align: top; color: #000000">14</font><font style="color: #000000">&#xA0;A
total of 26,675 participants were enrolled across 277 locations in
17 countries, including 14 sites in Japan.</font><font style="font-size: 70%; vertical-align: top; color: #000000">14</font><font style="color: #000000">&#xA0;The
trial's primary endpoint was vaccine efficacy against
RSV-LRTD</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">after
one RSV season following a single dose of
the&#xA0;vaccine.</font><font style="font-size: 70%; vertical-align: top; color: #000000">14</font><font style="color: #000000">&#xA0;There
were also efficacy, safety and immunogenicity secondary and
tertiary endpoints.</font><font style="font-size: 70%; vertical-align: top; color: #000000">14</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About the NCT05921903 trial</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">NCT05921903 is a Phase IIb, open-label,
multi-country, descriptive immunogenicity and safety
trial</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">in&#xA0;IC</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">participants
who were recipients of lung or kidney transplant, and aged 18 years
and above at increased risk for severe lower respiratory tract
disease (LRTD) caused by RSV (n=261).</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">The
trial compared one (n=131) versus two (n=130) doses of GSK's RSV
vaccine in IC and AIR participants, and also compared to a control
group of non-immunocompromised adults aged 50 and above receiving a
single dose (n=125).</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">A
total of 386 participants were enrolled across 46 locations in
eight countries, including eight sites in Japan.</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">The
trial's co</font><font style="color: #000000; font-family: Times New Roman">-</font><font style="color: #000000">primary endpoints were RSV-A and RSV-B
neutralisation titres following a first and a second dose of GSK's
RSV vaccine, measured at approximatively one month (30-42 days)
after the respective vaccination, expressed as mean geometric
increase post dose two relative to post dose
one.</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">There
were also safety and immunogenicity secondary and tertiary
endpoints.</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
The results demonstrated that a single dose of the vaccine showed a
robust immune response in the study population.</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font><font style="color: #000000">&#xA0;The
safety profile was consistent with findings from the broader Phase
III programme that supported the initial approval, with the most
common adverse events being injection site pain, myalgia,
fatigue,</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">arthralgia
and headache.</font><font style="font-size: 70%; vertical-align: top; color: #000000">15</font></font></div>
<br>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About RSV in adults</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">RSV</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">is
a common contagious virus affecting the lungs and breathing
passages and impacts an estimated 64 million people of all ages
globally every year.</font><font style="font-size: 70%; vertical-align: top; color: #000000">7</font><font style="color: #000000">&#xA0;Adults
can be at increased risk for RSV disease due to certain
comorbidities, immune compromised status, or advanced
age.</font><font style="font-size: 70%; vertical-align: top; color: #000000">6</font><font style="color: #000000">&#xA0;RSV
can exacerbate</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">certain</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">conditions,
including COPD, asthma, and chronic heart failure and can lead to
severe outcomes, such as pneumonia, hospitalisation, and
death.</font><font style="font-size: 70%; vertical-align: top; color: #000000">6</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000">The
true number of RSV-related cases is likely underestimated due to
lack of routine testing.</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[19]</font><font style="font-size: 70%; vertical-align: top; color: #000000">,</font><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">[20]</font></font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
About GSK</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF">www.gsk.com</font><font style="color: #000000">.</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 40%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
GSK enquiries</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Media:</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Tim
Foley</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
20 8047 5502</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Simon
Moore</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
20 8047 5502</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Kathleen
Quinn</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+1 202
603 5003</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Washington
DC)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Alison
Hunt</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
+1 540 742 3391</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Washington
DC)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Investor
Relations:</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Constantin
Fest</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
7831 826525</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">James
Dodwell</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
20 8047 2406</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Mick
Readey</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
7990 339653</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Steph
Mountifield</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
7796 707505</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Sam
Piper</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+44 (0)
7824 525779</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(London)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Jeff
McLaughlin</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+1 215
751 7002</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Philadelphia)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 30%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Frannie
DeFranco</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">+1 215
751 3126</font></div>
</td>
<td style="vertical-align: top; width: 25%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Philadelphia)</font></div>
</td>
</tr></table>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Cautionary statement regarding forward-looking
statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2025, and
GSK's Q1 Results for 2026.</font></div>
<div style="text-align: justify"><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: -2px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Registered in England &amp; Wales:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: -2px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">No.
3888792</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: -2px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
Registered Office:</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">79
New Oxford Street</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">London</font></div>
<div><font style="color: #000000; font-family: Times New Roman; font-size: 13px">WC1A
1DG</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: -2px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
References:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: auto; margin-right: auto; margin-bottom: 6px; width: 25%; height: 2px; background-color: #c7c7c7">
<!--line--></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[1]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">E-Stat:
Statistics of Japan. Available at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.e-stat.go.jp/en/stat-search/files?page=1&amp;layout=datalist&amp;toukei=00200524&amp;tstat=000000090001&amp;cycle=1&amp;tclass1=000001011678&amp;tclass2val=0</font><font style="color: #000000; font-size: 13px">.
Last accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[2]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Saito
Y,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Prevalence of
multimorbidity and its associations with hospitalisation or death
in Japan 2014-2019: a retrospective cohort study using nationwide
medical claims data in the middle-aged
generation.&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">BMJ
Open</font><font style="color: #000000; font-size: 13px">.
2023;13(5):e063216.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[3]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Njue
A,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Systematic Literature
Review of Risk Factors for Poor Outcomes Among Adults With
Respiratory Syncytial Virus Infection in High-Income Countries.
Open Forum Infectious Diseases (2023) 10(11):
ofad513.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[4]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Montiel
J,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;The
risk of cardiac disease events after respiratory syncytial virus
disease: a systematic literature review and meta-analysis. European
Respiratory Review (2026); 35:250160.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[5]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Penders
Y,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et&#x202F;al.</font><font style="color: #000000; font-size: 13px">&#xA0;Burden
of Respiratory Syncytial Virus Disease in Adults with Asthma and
Chronic Obstructive Pulmonary Disease: A Systematic Literature
Review. Current Allergy and Asthma Reports.
2025;25:14.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[6]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Falsey
AR,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Respiratory syncytial virus
infection in elderly and high-risk adults.&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">New Engl J
Med</font><font style="color: #000000; font-size: 13px">.
2005;352:1749-1759.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[7]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">National
Institute of Allergy and Infectious Diseases, Respiratory Syncytial
Virus (RSV). Available at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv</font><font style="color: #000000; font-size: 13px">.
Last accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[8]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Branche
AR;&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Incidence of Respiratory
Syncytial Virus Infection Among Hospitalized Adults, 2017-2020.
Clin&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Infect
Dis</font><font style="color: #000000; font-size: 13px">.2022;74;1004-1011.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[9]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Hviid
A,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Cardiovascular Events 1
Year After Respiratory Syncytial Virus Infection in Adults. JAMA
Netw Open. 2025;8(12):e2547618.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[10]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Liang
C,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Risk
of Cardiorespiratory Events Following Respiratory Syncytial
Virus-Related Hospitalization. JAMA Netw Open.
2026;9(2):e2556767</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[11]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Sudnik
P,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Comprehensive Analysis of
Cardiovascular Events and Risk Factors in Patients Hospitalized
With Respiratory Syncytial Virus. Clin Infect Dis. 2026 Feb
25;82(2):e396-e403.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[12]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Woodruff
R,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al.</font><font style="color: #000000; font-size: 13px">&#xA0;Acute
Cardiac Events in Hospitalized Older Adults With Respiratory
Syncytial Virus Infection. JAMA Intern Med.
2024;184(6):602-611.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[13]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Clinicaltrials.gov.
A Study on the Immune Response and Safety of Vaccine Against
Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of
Age at Increased Risk for Respiratory Syncytial Virus Disease,
Compared to Older Adults 60 Years of Age and Above. Available
at:&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/study/NCT06389487</font><font style="color: #000000; font-size: 13px">.
Last accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[14]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Clinicaltrials.gov.
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus
(RSV) Vaccine in Adults Aged 60 Years and Above. Available
at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/study/NCT04886596</font><font style="color: #000000; font-size: 13px">.
Last accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[15]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Clinicaltrials.gov.
A Study on the Immune Response and Safety of an RSV Vaccine When
Given to Adults 18 Years of Age and Above Who Received Lung or
Kidney Transplant and Are at an Increased Risk of Respiratory
Syncytial Virus Lower Respiratory Tract Disease and Compared to
Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023).
Available at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://clinicaltrials.gov/study/NCT05921903</font><font style="color: #000000; font-size: 13px">.
Last accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[16]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">GSK.
Arexvy. US Prescribing Information. Available
at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Arexvy/pdf/AREXVY.PDF</font><font style="color: #000000; font-size: 13px">.
Last accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[17]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">EMA.
Arexvy. Summary of Product Characteristics. Available
at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.ema.europa.eu/en/documents/product-information/arexvy-epar-product-information_en.pdf</font><font style="color: #000000; font-size: 13px">.
Last&#xA0;accessed: May 2026.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[18]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Japan
Pharmaceuticals and Medical Devices Agency. Pharmaceuticals
Information. Available at:</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="text-decoration: underline; color: #0000FF; font-size: 13px">https://www.pmda.go.jp/PmdaSearch/iyakuSearch/</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Last
accessed May 2026</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[19]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">G&#xFC;nen
H,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al</font><font style="color: #000000; font-size: 13px">. Key
Challenges to Understanding the Burden of Respiratory Syncytial
Virus in Older Adults in Southeast Asia, the Middle East, and North
Africa: An Expert Perspective.&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">Adv
Ther.</font><font style="color: #000000; font-size: 13px">&#xA0;2024;41(11):4312-4334.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 70%; vertical-align: top; text-decoration: underline; color: #0000FF">
[20]</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font><font style="color: #000000; font-size: 13px">Grace
M,&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">et
al</font><font style="color: #000000; font-size: 13px">. Economic
burden of respiratory syncytial virus infection in adults: a
systematic literature review.&#xA0;</font><font style="font-style: italic; color: #000000; font-size: 13px">J Med
Econ</font><font style="color: #000000; font-size: 13px">.&#xA0;2023;26(1):742-759.</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
GSK plc</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Registrant)</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:&#xA0;May
18, 2026</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:/s/&#xA0;VICTORIA
WHYTE</font></div>
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">--------------------------</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Victoria&#xA0;Whyte</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Authorised
Signatory for and on</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 48%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 52%">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">behalf
of GSK plc</font></div>
</td>
</tr></table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
